The concept of indicator condition guided HIV testing is an approach by which health care practitioners can be encouraged to offer tests to more patients based on suspicion of HIV. The HIDES study provided evidence on HIV prevalence for various conditions and diseases with HIV association.
1. Implement surveys to assess HIV prevalence for one or more diseases and/or conditions within a specific segment of the population not yet diagnosed with HIV and that present for care with the specific disease/condition.
- Presenting for care of malignant lymphoma, irrespective of type - patient information leaflet template
- Presenting for care of cervical or anal dysplasia or cancer, (Cervical CIN II and above) - patient information leaflet template CC - patient information leaflet template AC
- Presenting for care of Hepatitis B or C virus infection (acute or chronic – and irrespective of time of diagnosis relative to time of survey),
- Presenting with ongoing mononucleosis-like illness -patient information leaflet template
- Presenting with unexplained leukocytopenia or thrombocytopenia lasting at least 4 weeks -patient information leaflet template
Procedures for capturing data for ongoing mononucleosis-like illness from the laboratory
- Presenting with seborrheic dermatitis / exanthema -patient information leaflet template
- Presenting with pneumonia, admitted to hospital for at least 24h - patient information leaflet template
- Presenting with unexplained lymphadenopathy - patient information leaflet template
- Presenting with peripheral neuropathy of unknown cause (diagnosed by neurologist) - patient information leaflet template
- Presenting with primary lung cancer - patient information leaflet template
- Presenting with severe or recalcitrant psoriasis (newly diagnosed) - patient information leaflet template
2. Launch, implement and evaluate an audit system of the performance of HIV testing of persons presenting with a condition which has already been established as an indicator for HIV testing.
- Non-hodgkin’s lymphoma
- Anal cancer
- Cervical cancer
- Hep B and C
- Candida esophagitis
Presentations and Publications
Auditing HIV Testing Rates across Europe: Results from the HIDES 2 Study
Raben D, Mocroft A, Rayment M, Mitsura VM, Hadziosmanovic V, Sthoeger ZM, Palfreeman A, Morris S, Kutsyna G, Vassilenko A, Minton J, Necsoi C, Estrada VP, Grzeszczuk A, Johansson VS, Begovac J, Ong EL, Cabié A, Ajana F, Celesia BM, Maltez F, Kitchen M, Comi L, Dragsted UB, Clumeck N, Gatell J, Gazzard B, d'Arminio Monforte A, Rockstroh J, Yazdanpanah Y, Champenois K, Jakobsen ML, Sullivan A, Lundgren JD; HIDES Audit Study Group.
PLoS One. 2015 Nov 11;10(11):e0140845. doi: 10.1371/journal.pone.0140845. eCollection 2015.
Feasibility and Effectiveness of Indicator Condition Guided Testing for HIV: Results from HIDES I (HIV Indicator Diseases across Europe Study)
Sullivan AK, Raben D, Reekie J, Rayment M, Mocroft A, Esser S, Leon A, Begovac J, Brinkman K, Zangerle R, Grzeszczuk A, Vassilenko A, Hadziosmanovic V, Krasnov M, Sönnerborg A, Clumeck N, Gatell J, Gazzard B, Monforte Ad, Rockstroh J, Lundgren JD
PLoS One. 2013;8(1):e52845. doi: 10.1371/journal.pone.0052845
HIDES2 presentation: 14th European Aids Conference, Friday 18th October 2013 in Brussels
A Vassilenko, Belarusian State Medical University, Minsk, Belarus.
ZM Sthoeger, Ben Ari Institute of Clinical Immunology, Rehovot, Israel.
A Cabié, Centre Hospitalier Universitaire de Fort de France, Fort de France, Martinique.
E Senneville, Centre Hospitalier de Tourcoing, Tourcoing, France.
B Gazzard, A Sullivan, Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom.
JD Lundgren, Dorthe Raben, CHIP, Rigshospitalet, Copenhagen, Denmark.
V Hadziosmanovic, Clinical Center University of Sarajevo, Infectious Diseases Clinic, Sarajevo, Bosnia.
VM Mitsura, Gomel State Medical University, Gomel, Belarus.
Y Yazdanapanah, AP-HP, Hôpital Bichat, Service de Biostatistique, Paris, France.
J Gatell, Hospital Clinic de Barcelona, Barcelona, Spain.
F Maltez, Hospital Curry Cabral, Lisbon, Portugal.
V Perez Estrada, Hospital Universitario San Carlos, Madrid, Spain.
Y Yazdanapanah, IAME, UMR 1137, INSERM, Paris, France.
V Svedhem-Johansson, A Sönnerborg, Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
G Kutsyna, Luhansk AIDS Center, Luhansk, Ukraine.
R Flisiak, A Grzeszczuk, Medical University of Bialystok, Department of Infectious Diseases and Hepatology, Bialystok, Poland.
R Zangerle, Medical University of Innsbruck Innsbruck, Austria.
UB Dragsted, Roskilde Hospital, Roskilde, Denmark.
N Clumeck, C Nescoi, Saint-Pierre University Hospital, Brussels, Belgium.
A d'Arminio Monforte, Unit of Infectious Diseases, San Paolo Hospital, Milan, Italy.
J Minton, St James's University Hospital, Leeds, United Kingdom.
EL C Ong, The Newcastle upon Tyne Hospital, Newcastle, United Kingdom.
A Mocroft, University College London, London, United Kingdom.
J Rockstroh, University of Bonn, Bonn, Germany.
M Celesia, Unit of Infectious Diseases, University of Catania, ARNAS Garibaldi, Catania, Italy.
J Begovac, University Hospital of Infectious Diseases, Zagreb, Croatia.
A Palfreeman, University Hospitals of Leicester NHS Trust, LeicesteC Leen, Western General Hospital, Edinburgh, United Kingdom.C Leen, Western General Hospital, Edinburgh, United Kingdom.r, United Kingdom.
IAME, UMR 1137, Univ Paris Diderot, Sorbonne Paris Cité, Paris, France.
C Leen, Western General Hospital, Edinburgh, United Kingdom.